Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of On-Body Delivery System vs Autoinjector in Healthy Participants
NCT04848402Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Device. Started Sep 2021; status: completed.
Beyond the preview
Go deeper on NCT04848402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848402.